Phase II, Multicenter, Sixteen-Week, Randomized, Double Blind, Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults with Down Syndrome — Study Subjects Wanted

A team of medical doctors and psychologists at the Case Western Reserve University, University Hospitals, and the Cleveland Clinic is investigating the effects of memantine on individuals with Down syndrome who are between the ages 15 and 32. Memantine is a medication FDA-approved for the treatment of Alzheimer's disease, but it is not approved for use in persons with Down syndrome. This study was designed to examine whether or not this medication is safe and if it can improve memory and learning skills in adolescents and young adults with Down syndrome.

This study requires the participant and his or her primary caregiver to complete five to seven outpatient visits to University Hospitals in Cleveland, Ohio. Psychological and medical tests will take place during the visits. The tests, medication, and medical care related to the study are provided free of charge. Parking will be validated, and mileage can be reimbursed for those traveling 20 miles or more to come to the study.

If you, or someone you know, would be interested and meet the following requirements:

- 15-32 years of age
- medically diagnosed with Down syndrome
- in good general health and not pregnant
- able to swallow medicine capsules (crushing of capsules will not be permitted)
- have a reliable caregiver or family member who agrees to come with the participant to all visits, provide information about the participant, and ensure compliance with the medication schedule
- know enough English to be capable of reliably completing study tests

The study Principal Investigator is Alberto Costa, MD, PhD
Department of Pediatrics, Division of Pediatric Neurology
Case Western Reserve University and University Hospitals

For more information, please call or E-mail the study coordinator, Ms. Melissa Stasko
(216-844-7281, Melissa.Stasko@case.edu)

IRB Number 06-14-41, approval date 10/18/2014